SB

Sagimet Biosciences Inc.

SGMT·NASDAQ

$7.06

+4.3%
HealthcareBiotechnology

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

At a Glance

Live Snapshot
Market Cap$230.02M
EPS-1.5800
P/E Ratio-4.47
Earnings Date08/12/2026

sgmt

Cost of Revenue

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

SB

Sagimet Biosciences Inc. Competitors Analysis of Cost of Revenue

SGMT · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
0.00
N/AN/AN/A 
0.00
N/AN/AN/A
416.00K
-81.9%-69.9%N/A
129.00K
-86.2%N/A4.9%
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
17.05M
-39.4%-22.6%N/A
3.65M
1.1%29.9%N/A
4.59M
N/AN/AN/A
0.00
N/AN/AN/A
3.02M
N/AN/A26.3%
3.33M
N/AN/AN/A
4.10M
N/AN/AN/A
SB

Sagimet Biosciences Inc. Fair Value Envelope

SGMT · NASDAQ

Our analysis suggests that SGMT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.0599, this represents a potential HIDDEN relative to our calculated worth for Sagimet Biosciences Inc..

Intrinsic Value
Current Price: $7.0599